Welcome to our dedicated page for Inventiva S.A. SEC filings (Ticker: IVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inventiva S.A. American Depositary Shares (IVA) SEC filings page brings together the company’s regulatory disclosures as a foreign private issuer. Inventiva reports under the Exchange Act on Form 20-F and furnishes current information on Form 6-K, making these filings a primary source of insight into its biopharmaceutical research activities and corporate actions.
Recent Form 6-K filings referenced for Inventiva include press releases, interim financial reports, notices and documentation for Ordinary and Extraordinary General Meetings, proxy cards and voting instructions for holders of American Depositary Shares. One Form 6-K dated November 13, 2025 describes an underwriting agreement with Leerink Partners LLC and Piper Sandler & Co. for a public offering of ADSs under a shelf registration statement on Form F-3, illustrating how the company uses SEC-registered offerings to raise capital.
On this page, users can access Inventiva’s filings as they are made available through EDGAR, including annual reports on Form 20-F and current reports on Form 6-K. These documents may cover topics such as interim financial information, shareholder meeting procedures, and legal opinions related to securities offerings. For a biopharmaceutical company focused on drug candidates acting on nuclear receptors, transcription factors and epigenetic modulation, these filings help clarify how research programs and partnerships are reflected in its regulatory reporting.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in plain language, helping readers interpret complex documents such as registration statements on Form F-3 or detailed exhibits attached to Form 6-K. Real-time updates from EDGAR, combined with simplified explanations, allow investors to review Inventiva’s regulatory history, capital-raising transactions and governance disclosures in a more accessible format.
Andera Partners and affiliated investors report a 7.7% beneficial stake in Inventiva S.A., totaling 14,114,476 ordinary shares as of December 31, 2025. The shares are held through BioDiscovery 6 FPCI, which owns 12,296,295 ordinary shares and 1,818,181 American Depositary Shares, each ADS representing one ordinary share.
Andera Partners is the management company of BioDiscovery 6, and its managing partners, Stephane Bergez and Francois Xavier Mauron, may be deemed to share voting and dispositive power over these securities. The filers certify the holdings were not acquired to change or influence control of Inventiva.
Inventiva S.A. reported an updated ownership disclosure from Sofinnova-affiliated investors. As of December 31, 2025, Sofinnova Crossover I SLP beneficially owns 8,433,227 ordinary shares, corresponding to 12,332,804 voting rights, representing 5.6% of Inventiva’s 221,065,508 voting rights outstanding as of January 31, 2026.
Sofinnova Crossover II SLP holds 6,753,246 ordinary shares and voting rights, or 3.1% of voting rights. Sofinnova Partners SAS, as management company of both funds, together with investment committee members Antoine Papiernik, Cedric Moreau, Kinam Hong, Joseph Anderson and Jacques Theurillat, are each reported with 15,186,473 shares and 19,086,050 voting rights, or 8.6% of voting rights.
The individuals state that this report should not be construed as an admission that they are beneficial owners of the securities for Section 13(d) purposes.
Inventiva S.A. received an updated ownership report showing that Great Point Partners, LLC, together with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, beneficially owns 6,783,269 ordinary shares, representing 3.49% of the company’s share class.
This total includes 3,449,937 shares of common stock held outright and warrants to purchase a further 3,333,332 shares of common stock, all treated as beneficially owned. The filers report no sole voting or dispositive power, instead sharing both voting and disposal power over all reported shares, and state that the holdings are not intended to change or influence control of Inventiva.
Inventiva S.A. reported certain preliminary, unaudited figures for 2025, highlighting a strengthened cash position following major financings. As of December 31, 2025, cash and cash equivalents were €99.3 million and short-term deposits were €131.6 million, supporting the company’s MASH-focused clinical pipeline.
Net cash used in operating activities rose to (€104.6) million from (€85.9) million, driven by pipeline prioritization, lower licensing revenues from CTTQ, and higher general and administrative expenses, while R&D expenses decreased slightly to €86.9 million from €90.9 million. Net cash used in investing activities was (€133.2) million, mainly from new short-term deposits.
Net cash generated by financing activities reached €241.1 million, including €115.6 million of gross proceeds from the second tranche of a structured financing and $172.5 million of gross proceeds from a U.S. public offering. Revenues declined to €4.5 million from €9.2 million in 2024. Based on its current plan, Inventiva estimates its cash, cash equivalents, and short-term deposits can fund operations until the middle of the first quarter of 2027, with a potential extension to the middle of the third quarter of 2027 if Tranche 3 warrants are fully exercised.
Eventide Asset Management, LLC, together with Finny Kuruvilla and Robin C. John, reports beneficial ownership of 9,368,517 Inventiva S.A. ordinary shares, representing 4.6% of the class as of December 31, 2025.
Eventide has sole voting and dispositive power over 9,368,517 shares, while Kuruvilla and John share voting and dispositive power over the same amount. The group files as passive investors, certifying the holdings are not for changing or influencing control, and expressly disclaims beneficial ownership under Rule 13d-4.
Deep Track Capital, its master fund, and David Kroin have filed a Schedule 13G reporting a significant passive stake in Inventiva S.A. They report beneficial ownership of 11,668,983 ordinary shares and related instruments, representing 6.07% of the class as of January 30, 2026, based on 192,329,222 shares outstanding as of December 31, 2025.
The position includes 8,504,604 ordinary shares, 3,164,379 American Depository Shares and 9,999,999 warrants with a 1.50 EUR exercise price. The warrants are exercisable only if a “T3 Triggering Event” occurs, tied to NATiV3 trial topline results meeting key endpoints by June 15, 2027, and must be exercised no later than July 30, 2027. A 4.99% beneficial ownership cap limits how much can be held through warrant exercise.
The filers certify the securities are not held to change or influence control of Inventiva S.A. and characterize themselves as passive investors under Schedule 13G.
Inventiva S.A. announced an underwritten public offering of 38,961,038 ADSs at $3.85 per ADS, with a 30‑day option for underwriters to purchase up to 5,844,155 additional ADSs. The company expects net proceeds of approximately $140.1 million, or $161.2 million if the option is exercised in full, after underwriting commissions and estimated expenses.
The offering is being conducted under Inventiva’s Form F‑3 shelf that was deemed effective on November 3, 2025, and is expected to close on November 17, 2025, subject to customary closing conditions. Leerink Partners LLC and Piper Sandler & Co. are acting as underwriters. A legal opinion from Gide Loyrette Nouel A.A.R.P.I. has been filed in support of the issuance.
Inventiva S.A. (IVA) launched a primary offering of 38,961,038 American Depositary Shares at $3.85 per ADS under its shelf registration. The pricing implies a total offering size of $149,999,996, with underwriting commissions of $8,999,999 and estimated net proceeds of approximately $140.1 million. The company also granted underwriters a 30‑day option to purchase up to 5,844,155 additional ADSs at the public offering price, less commissions.
Inventiva plans to use roughly 80% of the proceeds to fund its NATiV3 Phase 3 MASH trial, prepare and initiate an outcomes trial, and support commercialization activities, and about 20% for working capital and general corporate purposes. Ordinary shares outstanding are expected to be 178,112,312 after the offering, or 183,956,467 if the option is fully exercised. The company notes immediate dilution of $3.12 per ADS to new investors.